Company / R&D Expense
Avanos Medical, Inc. R&D Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$23.3M
FY2025
5-year range
$23.3M / $30.6M
FY2021-FY2025
Trend
-11.1%
vs FY2024
Sector context
#91 of 105
Health Care
What the data says
Avanos Medical, Inc.'s r&d expense of $23M is lower than 87% of companies in the Health Care sector (FY2025). R&D Expense has declined for 7 consecutive years, from $42M in FY2018 to $23M in FY2025.
Based on SEC 10-K filings.
$23M in FY2025 with a 5-year CAGR of -7.8%.
Declined from $27M to $23M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -7.2%
- 5-Year CAGR
- -7.8%
- 10-Year CAGR
- -
Sector benchmark
Bottom 13% in Health CareTop 87% of 105This company $23.3M Sector average $284.2M
▼
-91.8% below sector average
Key checks
Key Insights
- Avanos Medical, Inc.'s r&d expense has declined for 7 consecutive years.
- 5-year CAGR of -7.8%, indicating a declining trend.
- In FY2025, r&d expense decreased 11.1% year-over-year.
- Ranks #91 out of 105 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 1.09 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $23.3M | -11.1% |
| FY2024 | $26.2M | -3.7% |
| FY2023 | $27.2M | -6.8% |
| FY2022 | $29.2M | -4.6% |
| FY2021 | $30.6M | -12.3% |
| FY2020 | $34.9M | -7.4% |
| FY2019 | $37.7M | -9.8% |
| FY2018 | $41.8M | +9.4% |
| FY2017 | $38.2M | -0.5% |
| FY2016 | $38.4M | +39.1% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026